The purpose of this investigation was to explore patients’ and oncologists’ preferences for the characteristics of a pharmacological regimen for patients with advanced renal cell carcinoma (aRCC).
Cross-sectional observational study based on a discrete choice experiment (DCE) conducted in Spain.